SelectScience
Join Free
NewsClinical Diagnostics

Biodesix announces new master collaborative research agreement with leading US cancer center

Biodesix and Memorial Sloan Kettering have joined forces to advance oncology diagnostics

27 Nov 2024

Industry news

Biodesix logo

Biodesix, a leading diagnostic solutions company with a focus on lung diseases, has entered into a new master collaborative research agreement (MCRA) with Memorial Sloan Kettering Cancer Center (MSK) under which the teams will collaborate on a development plan for diagnostic tests aimed at improving the treatment of cancer.

Biodesix will utilize its array of genomics, proteomics, and data mining capabilities with the aim of developing and commercializing oncology biomarker assays in collaboration with MSK. Bio-Rad will provide its industry-leading digital PCR assay technology in support of this important work.

The collaborators, represented by Dr. Howard Scher (MSK) and Dr. Gary Pestano (Biodesix), shared an update at the 31st International Precision Medicine Tri-Con meeting (PMTC) on March 25, titled: An Industry | Academic Collaboration Framework Focused on Novel Diagnostic Test Development in Oncology.

“The expansion of our previous master sponsored research agreement (MSRA) into a master collaborative research agreement with MSK is a significant milestone for Biodesix and for biomarkers in oncology diagnostics. Biodesix looks forward to co-developing and validating new test concepts under these agreements,” said Scott Hutton, CEO, Biodesix.

“We look forward to working with Biodesix to develop the next generation of highly multiplexed digital PCR assays as part of our expanding oncology offering,” said Simon May, EVP and President of Life Sciences at Bio-Rad Laboratories. “Bio-Rad provides the leading solution for digital PCR, and we are committed to providing oncology researchers and commercial partners with technologies that enable everything from biomarker discovery to clinical trials and patient monitoring of minimal residual disease.”

Want the latest science news straight to your inbox? Become a SelectScience member for free today>>

Tags

Clinical GeneticsOncologyThe branch of medical science that deals with the diagnosis and treatment of cancer is known as oncology.Biomarker DiscoveryClinical biomarkers refer to substances related to known medical conditions that can be accurately measured <i>in vitro</i>. Biomarkers can be used to diagnose presence of a disease and indicate disease severity. The discovery of new biomarkers is incredibly valuable in the field of diagnostics.GenomicsGenomics is the study of genomes, focusing on the sequencing, analysis, and interpretation of genetic material. It is key in understanding genetic diseases, evolutionary biology, and personalized medicine. Techniques like next-generation sequencing (NGS) are commonly used in genomics research. Browse our peer-reviewed product directory to find the best genomics tools, compare products, check reviews, and get pricing directly from manufacturers.ProteomicsProteomics refers to the analysis of proteins through a variety of different experiments in order to understand structure and functionality. Typical techniques include protein purification and mass spectrometry. Droplet Digital PCRDroplet digital PCR (ddPCR) is a method of quantitative PCR that partitions a sample into droplets, allowing precise detection of low-abundance targets. It is commonly used in gene expression analysis and mutation detection. Explore ddPCR systems in our peer-reviewed product directory; compare products, check reviews, and get pricing directly from manufacturers.Precision MedicinePrecision medicine refers to the idea of customized healthcare, where medical decisions and treatments are tailored to the individual patient. Molecular diagnostics, companion diagnostics and Next Generation Sequencing (NGS) play a pivotal role in this approach.

Related articles